Potential Breakthrough in Measles Treatment: NanoViricides Develops Antiviral Drug

NanoViricides, Inc., a publicly traded company, is at the forefront of antiviral drug development. With declining measles vaccination rates in the USA, there is concern that measles could become endemic. To address this, NanoViricides is advancing its drug NV-387, a broad-spectrum antiviral. NV-387 has shown promise in preclinical trials against multiple viruses, including RSV and potentially measles, leveraging its ability to mimic heparan sulfate proteoglycans.

The company has completed early testing stages for NV-387 and plans to conduct animal model studies. This development gains significance as measles cases rise across the USA, with vaccination rates hindered by public distrust and vaccine-ineligible populations.

NV-387's safety profile was established in Phase I trials, with no adverse events noted. NanoViricides is now focusing on advancing into Phase II human clinical trials, positioning NV-387 as a pivotal drug for current and future measles outbreaks.